SEC Company Response from Autolus Therapeutics plc (AUTL) (CIK 0001730463) (AUTL) — Apr 8, 2019
Autolus Therapeutics plc (AUTL) (CIK 0001730463)
Date: April 8, 2019 · CIK: 0001730463 · Accession: 0001193125-19-100816
AI Filing Summary & Sentiment
Reasoning
Letter
Re: Autolus Therapeutics plc
April 8, 2019
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: Ms. Christine Westbrook
Registration Statement on Form F-1 (CIK No. 0001730463) (the “Registration Statement”)
Ms. Westbrook:
In connection with the above-referenced Registration Statement, and pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), we, as representatives of the several underwriters, hereby join in the request of Autolus Therapeutics plc that the effectiveness of the Registration Statement be accelerated so that it will be declared effective at 4:30 p.m., Eastern Time, on April 10, 2019, or as soon thereafter as practicable.
Pursuant to Rule 460 under the Act, please be advised that we expect to take all reasonable steps to effect the distribution of as many copies of the preliminary prospectus, dated as of the date hereof (“Preliminary Prospectus”), to secure adequate distribution of the Preliminary Prospectus to underwriters, dealers, institutions and others, prior to the requested effective time of the Registration Statement.
In connection with the Preliminary Prospectus distribution for the above-referenced issue, we hereby confirm that we are, and the other prospective underwriters have confirmed that they are, complying with the 48-hour requirement as promulgated by Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.
[Remainder of page intentionally left blank]
Very truly yours,
GOLDMAN SACHS & CO. LLC
Show Raw Text
CORRESP 1 filename1.htm CORRESP April 8, 2019 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Ms. Christine Westbrook Re: Autolus Therapeutics plc Registration Statement on Form F-1 (CIK No. 0001730463) (the “Registration Statement”) Ms. Westbrook: In connection with the above-referenced Registration Statement, and pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), we, as representatives of the several underwriters, hereby join in the request of Autolus Therapeutics plc that the effectiveness of the Registration Statement be accelerated so that it will be declared effective at 4:30 p.m., Eastern Time, on April 10, 2019, or as soon thereafter as practicable. Pursuant to Rule 460 under the Act, please be advised that we expect to take all reasonable steps to effect the distribution of as many copies of the preliminary prospectus, dated as of the date hereof (“Preliminary Prospectus”), to secure adequate distribution of the Preliminary Prospectus to underwriters, dealers, institutions and others, prior to the requested effective time of the Registration Statement. In connection with the Preliminary Prospectus distribution for the above-referenced issue, we hereby confirm that we are, and the other prospective underwriters have confirmed that they are, complying with the 48-hour requirement as promulgated by Rule 15c2-8 under the Securities Exchange Act of 1934, as amended. [Remainder of page intentionally left blank] Very truly yours, GOLDMAN SACHS & CO. LLC JEFFERIES LLC As Representatives of the several Underwriters GOLDMAN SACHS & CO. LLC By: /s/ Elizabeth Wood Name: Elizabeth Wood Title: Managing Director JEFFERIES LLC By: /s/ Matthew Kim Name: Matthew Kim Title: Managing Director [Signature Page to Request for Acceleration of Effectiveness]